Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Essential Thrombocythemia: early-phase trial registry
9 of 17 indexed Essential Thrombocythemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 9 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Essential Thrombocythemia: 17 US clinical trials tracked, 9 recruiting.
Essential Thrombocythemia is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition essential-thrombocythemia
OPEN 9 | RECR 53% | LATE 3 | EARLY 13 | RANK #1004 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adenoid Cystic Carcinoma (53% recruiting · 17 trials)
Essential Thrombocythemia lists 9 open slots (53% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Essential Thrombocythemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Essential Thrombocythemia is recruiting above its size-band peers.
9 of 17 indexed trials (52.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Essential Thrombocythemia research.
National Cancer Institute (NCI) accounts for 3 of 17 trials (17.6%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Essential Thrombocythemia trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 17 trials that report a genuine target (sentinel values excluded). 13 of those (76.5%) plan for fewer than 100 participants.
-
Essential Thrombocythemia research is mostly interventional.
16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Merck Sharp & Dohme
NCT06079879
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Merck Sharp & Dohme
NCT06456346
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05031897
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
NCT06661915
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Massachusetts General Hospital
NCT04644211
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
NCT06063486
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
NCT05123365
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT04282187
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Marina Kremyanskaya
NCT05025488
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
PharmaEssentia
NCT04285086
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
PharmaEssentia
NCT05482971
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03862157
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03289910
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
Terrence J Bradley, MD
NCT04262141
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
NCT01520220
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
National Cancer Institute (NCI)
NCT00047190
Familial Myeloproliferative Disorders
Icahn School of Medicine at Mount Sinai
NCT00666289
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Essential Thrombocythemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Essential Thrombocythemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Essential Thrombocythemia page
17 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Essential Thrombocythemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Essential Thrombocythemia trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Essential Thrombocythemia condition card totals 17 registered trials; most-linked intervention Ruxolitinib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.